Incretin mimetics
https://themeditary.com/dosage-information/bydureon-dosage-1948.html

Bydureon Dosage

Drug Detail:Bydureon pen (Exenatide (bydureon) [ ex-en-a-tide ])

Generic Name: EXENATIDE 2mg in 0.65mL

Dosage Form: injection, suspension, extended release

Drug Class: Incretin mimetics

Contents
Uses Warnings Before Taking Dosage Side effects Interactions FAQ

Recommended Dosing

•
The recommended dose of BYDUREON is 2 mg subcutaneously once every 7 days (weekly). The dose can be administered at any time of day, with or without meals.
•
Discontinue an immediate- or extended-release exenatide product prior to initiation of BYDUREON. Patients changing from immediate-release exenatide to BYDUREON may experience transient (approximately 2 to 4 weeks) elevations in blood glucose concentrations.
•
The day of weekly administration can be changed, if necessary, as long as the last dose was administered 3 or more days before the new day of administration.
•
If a dose is missed, administer the dose as soon as noticed, provided the next regularly scheduled dose is due at least 3 days later. Thereafter, patients can resume their usual dosing schedule of once every 7 days (weekly).
•
If a dose is missed and the next regularly scheduled dose is due 1 or 2 days later, do not administer the missed dose and instead resume BYDUREON with the next regularly scheduled dose.

Administration Instructions

•
There are two presentations of BYDUREON (i.e., a single dose tray and a single dose pen). Each presentation of BYDUREON requires constitution prior to use to obtain a final concentration of 2 mg of exenatide per 0.65 mL of suspension.
•
​Prior to initiation, train patients and caregivers on proper mixing and injection [see Instruction for Use]. Instruct caregivers to assist pediatric patients with mixing and administration.
•
Inspect BYDUREON visually before use. The suspension should appear white to off-white and cloudy. Do not use if particulate matter is present or if discoloration is observed.
•
Immediately after the dose is prepared, administer BYDUREON subcutaneously to the abdomen, thigh, or upper arm region. Instruct patients to use a different injection site each week when injecting in the same region.
•
When using BYDUREON with insulin, always administer BYDUREON and insulin as separate injections and never mix the products. It is acceptable to inject BYDUREON and insulin in the same body region but the injections should not be adjacent to each other.
Share this Article
Latest News
Related Drugs